(Q38666768)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28649882%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

review article

1 reference

title

Neratinib for the treatment of HER2-positive early stage breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28649882%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28649882%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Ivan Marquez-Rodas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28649882%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

author name string

Isabel Echavarria

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28649882%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Yolanda Jerez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28649882%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

Miguel Martin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28649882%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

publication date

26 June 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28649882%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

23 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28649882%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28649882%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28649882%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

page(s)

669-679

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28649882%20AND%20SRC:MED&resulttype=core&format=json

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

23 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

ErbB receptors: new insights on mechanisms and biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

EGF-ERBB signalling: towards the systems level

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

HER2 therapy: molecular mechanisms of trastuzumab resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

The development of HKI-272 and related compounds for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Reversible covalent binding of neratinib to human serum albumin in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Characterization of HKI-272 covalent binding to human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Adaptive Randomization of Neratinib in Early Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737140.2017.1338954

10.1080/14737140.2017.1338954

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28649882%20AND%20SRC:MED&resulttype=core&format=json

23 March 2020

1 reference